These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 22114960)

  • 21. Direct-acting antiviral therapies for hepatitis C genotype 1 infection: a multiple treatment comparison meta-analysis.
    Cooper C; Lester R; Thorlund K; Druyts E; El Khoury AC; Yaya S; Mills EJ
    QJM; 2013 Feb; 106(2):153-63. PubMed ID: 23159839
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New treatments for chronic hepatitis C virus infection.
    Corouge M; Pol S
    Med Mal Infect; 2011 Nov; 41(11):579-87. PubMed ID: 21764234
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Telaprevir for chronic hepatitis C virus infection.
    Jesudian AB; Jacobson IM
    Clin Liver Dis; 2013 Feb; 17(1):47-62. PubMed ID: 23177282
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus.
    Kwong AD; Kauffman RS; Hurter P; Mueller P
    Nat Biotechnol; 2011 Nov; 29(11):993-1003. PubMed ID: 22068541
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The efficacy and safety of telaprevir-based regimens for treating chronic hepatitis C virus genotype 1 infection: a meta-analysis of randomized trials.
    Yang D; Liang HJ; Li D; Wei X; Ma L; Jia Z
    Intern Med; 2013; 52(6):653-60. PubMed ID: 23503406
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Seizures in patients with chronic hepatitis C treated with NS3/4A protease inhibitors: does pharmacological interaction play a role?
    Milazzo L; Falvella FS; Magni C; Gervasoni C; Peri AM; Cattaneo D; Antinori S; Vidale S
    Pharmacology; 2013; 92(5-6):235-7. PubMed ID: 24192929
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virus.
    Barritt AS; Fried MW
    Gastroenterology; 2012 May; 142(6):1314-1323.e1. PubMed ID: 22537438
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Simeprevir for the treatment of chronic hepatitis C genotype 1 infection.
    Takehara T
    Expert Rev Anti Infect Ther; 2014 Aug; 12(8):909-17. PubMed ID: 24882512
    [TBL] [Abstract][Full Text] [Related]  

  • 29. UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients.
    Ramachandran P; Fraser A; Agarwal K; Austin A; Brown A; Foster GR; Fox R; Hayes PC; Leen C; Mills PR; Mutimer DJ; Ryder SD; Dillon JF
    Aliment Pharmacol Ther; 2012 Mar; 35(6):647-62. PubMed ID: 22296568
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative effectiveness and safety study of triple therapy with simeprevir or telaprevir for non-cirrhotic patients with chronic hepatitis C virus genotype 1b infection.
    Ogawa E; Furusyo N; Kajiwara E; Nomura H; Kawano A; Takahashi K; Dohmen K; Satoh T; Azuma K; Nakamuta M; Koyanagi T; Kotoh K; Shimoda S; Hayashi J
    J Gastroenterol Hepatol; 2015 Dec; 30(12):1759-67. PubMed ID: 26095167
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Triple therapy with telaprevir: results in hepatitis C virus-genotype 1 infected relapsers and non-responders.
    Forestier N; Zeuzem S
    Liver Int; 2012 Feb; 32 Suppl 1():44-50. PubMed ID: 22212571
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anemia management in patients with chronic viral hepatitis C.
    Hynicka LM; Heil EL
    Ann Pharmacother; 2013 Feb; 47(2):228-36. PubMed ID: 23386076
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.
    Manns MP; Markova AA; Calle Serrano B; Cornberg M
    Liver Int; 2012 Feb; 32 Suppl 1():27-31. PubMed ID: 22212568
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New direct-acting antivirals' combination for the treatment of chronic hepatitis C.
    Asselah T; Marcellin P
    Liver Int; 2011 Jan; 31 Suppl 1():68-77. PubMed ID: 21205141
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Treatment of chronic hepatitis viral C: new associations].
    Ouzan D
    Presse Med; 2013 Jun; 42(6 Pt 1):977-82. PubMed ID: 23021659
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Triple combination treatment of chronic hepatitis C].
    Husa P
    Vnitr Lek; 2012; 58(7-8):588-90. PubMed ID: 23067190
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [New agents for the treatment of hepatitis C].
    Buti M; Homs M
    Enferm Infecc Microbiol Clin; 2012 Mar; 30(3):147-50. PubMed ID: 22118805
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of genotype 2 and 3 hepatitis C virus variants in patients treated with telaprevir demonstrates a consistent resistance profile across genotypes.
    De Meyer S; Ghys A; Foster GR; Beumont M; Van Baelen B; Lin TI; Dierynck I; Ceulemans H; Picchio G
    J Viral Hepat; 2013 Jun; 20(6):395-403. PubMed ID: 23647956
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Telaprevir or boceprevir based therapy for chronic hepatitis C infection: development of resistance-associated variants in treatment failure.
    Macartney MJ; Irish D; Bridge SH; Garcia-Diaz A; Booth CL; McCormick AL; Labbett W; Smith C; Velazquez C; Tanwar S; Trembling P; Jacobs M; Dusheiko G; Rosenberg W; Haque T
    Antiviral Res; 2014 May; 105():112-7. PubMed ID: 24594347
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.
    McHutchison JG; Everson GT; Gordon SC; Jacobson IM; Sulkowski M; Kauffman R; McNair L; Alam J; Muir AJ;
    N Engl J Med; 2009 Apr; 360(18):1827-38. PubMed ID: 19403902
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.